‘Magic mushrooms’ research gets OK from Indiana House committee
The U.S. Food and Drug Administration designated psilocybin as a “breakthrough therapy” for treatment-resistant depression in 2018 and for major depressive disorder in 2019.
The U.S. Food and Drug Administration designated psilocybin as a “breakthrough therapy” for treatment-resistant depression in 2018 and for major depressive disorder in 2019.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
The research published by the IU Richard M. Fairbanks School of Public Health found that one in five Indiana residents with mental illness do not receive the treatment they need.
A number of studies have found that people receiving vaccinations for flu and several other infectious diseases appear less likely than the unvaccinated to develop dementia, although scientists aren’t sure why.
Researcher Terry Loghmani and two colleagues have developed a medical device they say can help physical therapists monitor the level of pressure they apply to the soft tissue of patients seeking greater mobility and pain relief.
People who endured even mild cases of COVID-19 are at heightened risk two years later for lung problems, fatigue, diabetes and certain other health problems typical of long COVID, according to a new study that casts fresh light on the virus’s true toll.
The study did not say the medications cause dementia, only that there was an association between using the drugs and a higher risk of developing dementia.
Walther will provide a one-for-one match for donors who establish endowed children’s cancer research funds at Riley Children’s Foundation, a move that could result in at least $20 million for research of new treatments of children’s cancers.
Scientists don’t yet know what causes long COVID, the catch-all term for about 200 widely varying symptoms.
A large study showed that older adults with a higher risk of dementia may be able to reduce their risk of cognitive decline by almost 50 percent by using hearing aids.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
The National Institutes of Health awarded the grant to the Indiana Clinical and Translational Sciences Institute, a partnership among Indiana University, Purdue University and University of Notre Dame.
Fred Cate, IU’s vice president for research, informed federal officials that the research group had “a pattern of non-compliance” and had been warned several times against using expired materials.
Five of the top 10 research studies that received the most NIH funding at the medical school were for Alzheimer’s disease or brain aging, one of the school’s top priorities.
Dr. Rachel Patzer, director of the Health Services Research Center at the Emory University School of Medicine in Atlanta, will join Regenstrief Institute on May 1.
Researchers at Indiana University School of Medicine are hoping to gain new insights into the defect, called coarctation of the aorta, or narrowing of the aorta that obstructs blood flow to vital organs.
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
The high-tech approach allows a patient recovering from substance abuse to interact with potential future versions of himself or herself.
After 15 years of coaxing and cajoling the medical community to consider a different way to do brain surgery, NICO co-founder Jim Pearson has numbers to show more surgeons and investors are buying into his vision.
Here’s how beagles being bred for research by an Indianapolis-based company became the target of the largest animal welfare seizure in the Humane Society’s history.